Alcon Inc. (ALC) Stock: Price, Forecast & Analyst Target
Alcon Inc. (ALC) — MoonshotScore 78/100 (Strong band), calculated Oct 4, 2026. Price $63.76 (-0.28%), as of the Oct 2, 2026 trading session; market cap $31.1B. Expected results Nov 10, 2026.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 21.35× (market value Oct 2, 2026; cash Jun 30, 2026) · expected results Nov 10, 2026
Alcon Inc. · ALC · NYSE · Healthcare · Medical - Specialties
Research dated 2026-09-12: Alcon sells eye-surgery systems, implantable lenses, procedure consumables, contact lenses and ocular-health products under the ALC ticker. Equipment comparisons are becoming harder just as newer products are expected to contribute more, making sustained sales momentum and recovery in reported operating profit the defining test.
Price as of Oct 2, 2026
Key Statistics
MoonshotScore v2 · Alcon (ALC)
StrongWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality, a strong balance sheet and durable growth, at a cheap price, with no real weak spot. Business Quality: Solid; Financial Safety: Sound; Valuation: Fair; Growth Durability: Compounding; Momentum: Quiet.
- quarterly revenue $2.82B (Q2 FY2026, quarter ended Jun 2026)
- EPS beat 6 of 8
- Altman Z 2.54 · Piotroski F 8
Helping: business quality, balance-sheet strength, an attractive price, durable growth
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 77 | Strong | |
| 77 | Strong | |
| 77 | Strong | |
| 77 | Strong | |
| 78 | Strong | |
| 78 | Strong |
The score was 78 in the stored Oct 3, 2026 snapshot and remains 78 in the current publication computed Oct 4, 2026 (0).
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $63.76 | |
| Change on the day | -0.28% | |
| 52-week range | $61.84–$87.64 | |
| Market capitalisation | $31.1B | |
| Price / earnings (trailing) | 49.05 | |
| Shares traded on the day | 1.17M | |
| Beta (volatility vs the S&P 500) | 0.7 | |
| Dividends per share (last 12 months) | $0.36 | |
| Dividend yield (last 12 months) | 0.56% |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · below the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings call · management outlook
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Management outlook
For the second half of the year, we expect tougher equipment comparisons, partially offset by easier comparisons in contact lenses, particularly in the fourth quarter. We also expect launch contributions from TRYPTYR, Valeda, UNITY CS as well as PanOptix Pro in Europe to become more meaningful as we move through the balance of the year.
Timothy Stonesifer · Statement from
This guidance also reflects an anticipated refund of approximately $60 million from the U.S. government in the third quarter, of which we plan to reinvest approximately 2/3 back into the business.
Timothy Stonesifer · Statement from
Statement dates identify the earnings call, not a deadline. Management expectations and provider estimates can change.
Read management statementsOther perspectives
Council score for Alcon (ALC): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
4 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 28, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 5, 2026, except a card that shows its own read date.
Watch the ALC film — every key number, told as a short cinematic story
~2 min · open the film
What is Alcon (ALC), and what does it report?
Short answer · as of
Alcon is an eye-care manufacturer with Surgical and Vision Care operations, not simply a medical-equipment vendor. A cataract procedure can involve its diagnostics, visualization systems or surgical platform, followed by demand for implantable lenses, solutions, instruments and custom packs; Vision Care adds replenishment demand from contact lenses and ocular-health products.
Research dated 2026-09-12.
Alcon is an eye-care manufacturer with Surgical and Vision Care operations, not simply a medical-equipment vendor. A cataract procedure can involve its diagnostics, visualization systems or surgical platform, followed by demand for implantable lenses, solutions, instruments and custom packs; Vision Care adds replenishment demand from contact lenses and ocular-health products.
Consolidated revenue therefore blends equipment purchases, procedure-linked products and repeat consumer use. That mix matters because hospital capital budgets, surgical activity and contact-lens demand can move differently, while research spending supports products across the portfolio.
What do the latest results show for Alcon (ALC)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $2.82B.
Research dated 2026-09-12.
The latest income statement shows revenue and gross profit rising from the preceding period, but research and development expense surged, selling and administrative expense also increased, and reported operating profit nearly disappeared. The earnings record simultaneously shows sales and per-share earnings above expectations, so the headline beat did not translate into comparable reported operating conversion.
Management expects harder equipment comparisons to be partly offset by more favorable contact-lens comparisons. It also expects TRYPTYR, Valeda, UNITY CS and PanOptix Pro in Europe to contribute more as the year progresses, while planned reinvestment of a government refund and a broadly stable selling-and-administrative burden relative to sales could limit near-term profit flow-through.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $2.82B Jun 30, 2026
- Latest quarter · R&D
- $663.00M Jun 30, 2026
- Latest quarter · SG&A
- $964.00M Jun 30, 2026
- Latest quarter · FMP standardized operating result
- $11.00M Jun 30, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Jun 30, 2026 | $2.82B | $663.00M | $964.00M | $11.00M |
| Mar 31, 2026 | $2.65B | $240.24M | $844.27M | $410.86M |
| Dec 31, 2025 | $2.72B | $273.00M | $901.00M | $313.00M |
| Sep 30, 2025 | $2.61B | $250.00M | $865.00M | $332.00M |
USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $2.79B Aug 10, 2026
- Latest report · revenue estimate
- $2.72B Aug 10, 2026
- Latest report · revenue vs estimate
- Above estimate Aug 10, 2026
- Latest report · EPS vs estimate
- Above estimate Aug 10, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Aug 10, 2026 | $2.79B | $2.72B | $0.8400 | $0.7700 |
| May 5, 2026 | $2.65B | $2.64B | $0.8500 | $0.8000 |
| Feb 24, 2026 | $2.64B | $2.69B | $0.7800 | $0.7900 |
| Nov 11, 2025 | $2.61B | $2.71B | $0.7900 | $0.7700 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $2.82B | $0 | $0.00 (diluted) |
| Q1 FY2026 | $2.65B | $185M | $0.38 (diluted) |
| Q4 FY2025 | $2.72B | $217M | $0.44 (diluted) |
| Q3 FY2025 | $2.61B | $237M | $0.48 (diluted) |
What are the financial strengths and risks for Alcon (ALC)?
Short answer
Cash and short-term investments were $1.46B at the Jun 30, 2026 balance-sheet date. Operating cash flow was $510.00M for the quarter ended Jun 30, 2026, meaning operations generated cash. These figures do not establish a cash runway.
Research dated 2026-09-12.
Operating cash flow remained positive and exceeded capital spending throughout the reported window, giving Alcon internally generated funding despite uneven accounting profit. Annual revenue has advanced across successive reported periods, although the latest annual net result eased as research spending rose.
Debt substantially exceeds cash and short-term investments, even after long-term investments are included. Cash and short-term investments declined across the reported window, while the latest liquidity ratios indicate that short-term assets still cover short-term obligations; the strong quality screen does not remove the burden created by net debt and weak recent reported margins.
The business is most exposed when equipment demand slows while launch, research and commercial spending remain elevated. A rising annual dividend adds another recurring cash claim, so continued cash generation after capital spending matters more than the cash balance alone.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- $510.00M Jun 30, 2026
- Previous quarter · operating cash flow
- $409.88M Mar 31, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Jun 30, 2026 | $510.00M | −$96.00M |
| Mar 31, 2026 | $409.88M | −$136.30M |
| Dec 31, 2025 | $658.00M | −$201.00M |
| Sep 30, 2025 | $698.77M | −$160.08M |
Operating cash-flow bars share one scale and show magnitude; negative values mean cash used.
USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway.
What should you watch next at Alcon (ALC)?
Short answer · as of
The next earnings report is expected on Nov 10, 2026.
Research dated 2026-09-12.
Watch whether UNITY CS, TRYPTYR, Valeda and PanOptix Pro produce visible sales contributions while contact-lens comparisons improve. Those gains need to offset harder equipment comparisons without requiring selling and administrative spending to consume the benefit.
Reported operating conversion deserves particular attention after gross profit rose but operating profit nearly vanished. The scheduled earnings release can also test whether sales and per-share earnings continue to clear expectations and whether consensus assumptions for longer-run expansion remain plausible.
Cash flow offers the cleanest cross-check: operating cash should continue to cover capital spending, while cash and short-term investments should stabilize rather than extending their decline.
What management is planning
Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.
For the second half of the year, we expect tougher equipment comparisons, partially offset by easier comparisons in contact lenses, particularly in the fourth quarter. We also expect launch contributions from TRYPTYR, Valeda, UNITY CS as well as PanOptix Pro in Europe to become more meaningful as we move through the balance of the year.
Timothy Stonesifer ·
This guidance also reflects an anticipated refund of approximately $60 million from the U.S. government in the third quarter, of which we plan to reinvest approximately 2/3 back into the business.
Timothy Stonesifer ·
Based on these assumptions and our performance through the first half of the year, our guidance is as follows: We continue to expect constant currency sales growth of between 5% and 7%.
Timothy Stonesifer ·
As such, we expect SG&A spending for the second half to be consistent with last year on a percentage of sales basis.
Timothy Stonesifer ·
What the records here don't tell us
- No insider Form 4 transaction falls inside the window this page reads.
Checked against the records this page reads, on the dates shown above.
How does Alcon compare with its peers?
Short answer
Alcon's score ranks 4th of 8 in the bounded comparison shown, against 7 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-12.
Alcon combines capital equipment, procedure-specific consumables and implantable lenses with a separate contact-lens and ocular-health franchise. A pure equipment maker depends more directly on purchasing cycles, while a pure contact-lens business lacks Alcon’s exposure to surgical procedures and the associated demand for lenses, packs, solutions and instruments.
That breadth creates distinct demand rhythms inside the same company: equipment purchases can be intermittent, procedure products move with surgical activity, and Vision Care products depend more on replenishment. The mix can cushion weakness in a product category, but it can also leave strong sales growth paired with poor operating conversion when development and commercial spending rise.
| Company | Price | Market value | Score |
|---|---|---|---|
| $218.89 Oct 2, 2026 | $31.8B | 94 5-pillar Oct 4, 2026 | |
| $228.30 Oct 2, 2026 | $53.5B | 88 5-pillar Oct 4, 2026 | |
| $167.77 Oct 2, 2026 | $47.4B | 84 5-pillar Oct 4, 2026 | |
| Alcon (ALC) — this page | $63.76 | $31.1B | 78 |
| $258.21 Oct 2, 2026 | $42.5B | 73 5-pillar Oct 4, 2026 | |
| $176.80 Oct 2, 2026 | $48.7B | 72 5-pillar Oct 4, 2026 | |
| $1.10 Oct 2, 2026 | $47.9M | 44 5-pillar Oct 4, 2026 | |
| $19.01 Oct 2, 2026 | $394M | 32 5-pillar Oct 4, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $35.00 – $85.00
- Consensus target
- $74.88
- Median target
- $80.50
Consensus record · Captured .
Measured against a quoted price of $63.76 (as of Oct 2, 2026).
Who holds the shares?
Institutional ownership reported through 13F filings.
- Institutional ownership
- 49.4% Period end Jun 30, 2026
- Previous quarter · ownership
- 46.8% Prior to period end Jun 30, 2026
- Reporting holders
- 670 Period end Jun 30, 2026
- Previous quarter · holders
- 689 Prior to period end Jun 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Vanguard Capital Management LLC | 14,749,582 |
| Bank Of New York Mellon Corp | 13,057,962 |
| Norges Bank | 10,976,697 |
| Invesco Ltd. | 10,380,332 |
| Ako Capital Llp | 9,683,004 |
Quarterly filings lag the period end. Holder rows are names in the provider snapshot, not a verified ranking; individual filing dates are not supplied. Related managers may appear separately, so these positions are not summed. Holder snapshot as of Jun 30, 2026.
What has been published about Alcon (ALC)?
Common Questions About ALC (Healthcare)
Research dated 2026-09-12; the answers below are from that research, and the full attribution is under Sources. The last 3 questions are answered from this page's own dated data, not from the research.
How do UNITY CS and PanOptix Pro fit into Alcon’s growth plan?
UNITY CS expands Alcon’s cataract-surgery equipment offering, while PanOptix Pro adds to its implantable-lens portfolio. Management expects their launch contributions to become more meaningful as the year progresses.
Why do equipment and contact-lens comparisons pull Alcon in different directions?
Equipment demand reflects purchasing cycles for surgical systems, whereas contact lenses depend on repeat use and replenishment. Management expects harder equipment comparisons alongside more favorable contact-lens comparisons.
Why did Alcon’s reported operating profit weaken while gross profit rose?
Research and development expense increased sharply and selling and administrative expense also rose, absorbing the higher gross profit. The result was a steep deterioration in reported operating conversion despite higher revenue.
Does Alcon’s surgical model generate cash after capital spending?
Operating cash flow exceeded capital spending throughout the reported window. That cash generation is important because debt remains above cash and investments, while cash and short-term investments have declined.
What is the ALC stock price today?
The last price recorded on this page for Alcon Inc. (ALC) is $63.76, as of the Oct 2, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the ALC price target?
The analyst consensus price target for Alcon Inc. (ALC) is $74.88 (range $35.00 to $85.00, median $80.50), per FMP data captured Oct 4, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Does ALC pay a dividend?
Yes. Alcon Inc. (ALC) shows a trailing 12-month dividend yield of 0.56%, as of Oct 2, 2026, in the data on this page. Payout ratio and cash-flow coverage decide whether it can last, and past dividends do not guarantee future payments.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (83 figures)
The 83 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 2 facts from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
prod.outlook | Management outlook — call excerpts | Timothy Stonesifer (Aug 11, 2026): For the second half of the year, we expect tougher equipment comparisons, partially offset by easier comparisons in contact lenses, particularly in the fourth quarter. We also expect launch contributions from TRYPTYR, Valeda, UNITY CS as well as PanOptix Pro in Europe to become more meaningful as we move through the balance of the year. Timothy Stonesifer (Aug 11, 2026): This guidance also reflects an anticipated refund of approximately $60 million from the U.S. government in the third quarter, of which we plan to reinvest approximately 2/3 back into the business. Timothy Stonesifer (Aug 11, 2026): Based on these assumptions and our performance through the first half of the year, our guidance is as follows: We continue to expect constant currency sales growth of between 5% and 7%. Timothy Stonesifer (Aug 11, 2026): As such, we expect SG&A spending for the second half to be consistent with last year on a percentage of sales basis. | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) — Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. | |
id.hq | SEC filing business address | Fort Worth, TX | OFFICIAL | SEC EDGAR filer business address — The SEC filer business address. Our market-data provider separately lists "Chemin de Blandonnet 8, Geneva, GE, 1214, CH". The FMP company description names Geneva, Switzerland as the headquarters; this page uses the address in this row. |
FMP — 72 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.next | Next earnings date | Nov 10, 2026 | FMP | Financial Modeling Prep (FMP) earnings calendar — The date is our provider's estimate until the company confirms it. | |
px.last | Latest provided price | $63.76 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-04T21:14:25.157Z. | |
px.change | Change on the day | -0.28% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $31.1B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-02. FMP quote timestamp: 2026-10-02T20:00:03.000Z. Captured from FMP at 2026-10-04T21:14:23.317Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | −$0.18 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $2.82B | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
px.range52 | 52-week range | $61.84–$87.64 | FMP | Financial Modeling Prep (FMP) quote | |
px.pe | Price / earnings (trailing) | 49.05 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 1.17M | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 0.7 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | David J. Endicott | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
id.employees | Employees | 25,000 | FMP | Financial Modeling Prep (FMP) employee count, from the company's filing | |
fin.annual | Revenue and net result by fiscal year | 5 fiscal years, FY2021 through FY2025: FY2021 revenue $8.29B, net result $376.00M; FY2022 revenue $8.72B, net result $335.00M; FY2023 revenue $9.46B, net result $974.00M; FY2024 revenue $9.91B, net result $1.02B; FY2025 revenue $10.40B, net result $980.00M | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements | |
fin.gross_margin | Gross margin (trailing twelve months) | 56.5% | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.q_table.depth.2026-06-30.revenue_k | Revenue — period end 2026-06-30 | $2.82B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.rd_k | R&D — period end 2026-06-30 | $663.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.sga_k | SG&A — period end 2026-06-30 | $964.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.operating_result_k | FMP standardized operating result — period end 2026-06-30 | $11.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.revenue_k | Revenue — period end 2026-03-31 | $2.65B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.rd_k | R&D — period end 2026-03-31 | $240.24M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.sga_k | SG&A — period end 2026-03-31 | $844.27M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.operating_result_k | FMP standardized operating result — period end 2026-03-31 | $410.86M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.revenue_k | Revenue — period end 2025-12-31 | $2.72B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.rd_k | R&D — period end 2025-12-31 | $273.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.sga_k | SG&A — period end 2025-12-31 | $901.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.operating_result_k | FMP standardized operating result — period end 2025-12-31 | $313.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.revenue_k | Revenue — period end 2025-09-30 | $2.61B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.rd_k | R&D — period end 2025-09-30 | $250.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.sga_k | SG&A — period end 2025-09-30 | $865.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.operating_result_k | FMP standardized operating result — period end 2025-09-30 | $332.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
earn.history.depth.2026-08-10.revenue_actual | Revenue · reported — report date 2026-08-10 | $2.79B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-10.revenue_estimated | Revenue · estimate — report date 2026-08-10 | $2.72B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-10.eps_actual | EPS · reported — report date 2026-08-10 | $0.8400 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-10.eps_estimated | EPS · estimate — report date 2026-08-10 | $0.7700 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-05.revenue_actual | Revenue · reported — report date 2026-05-05 | $2.65B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-05.revenue_estimated | Revenue · estimate — report date 2026-05-05 | $2.64B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-05.eps_actual | EPS · reported — report date 2026-05-05 | $0.8500 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-05.eps_estimated | EPS · estimate — report date 2026-05-05 | $0.8000 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-24.revenue_actual | Revenue · reported — report date 2026-02-24 | $2.64B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-24.revenue_estimated | Revenue · estimate — report date 2026-02-24 | $2.69B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-24.eps_actual | EPS · reported — report date 2026-02-24 | $0.7800 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-24.eps_estimated | EPS · estimate — report date 2026-02-24 | $0.7900 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-11.revenue_actual | Revenue · reported — report date 2025-11-11 | $2.61B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-11.revenue_estimated | Revenue · estimate — report date 2025-11-11 | $2.71B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-11.eps_actual | EPS · reported — report date 2025-11-11 | $0.7900 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-11.eps_estimated | EPS · estimate — report date 2025-11-11 | $0.7700 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
fin.cash_investments | Cash and short-term investments | $1.46B | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. | |
fin.opcf_latest | Latest-quarter operating cash flow | $510.00M | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Period end: 2026-06-30. Negative operating cash flow means cash used. This figure is not a cash-runway estimate. | |
fin.long_term_investments | Long-term investments (classification unverified) | $768.00M | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.total_debt | Total debt | $5.30B | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.price_to_book | Price to book value | 1.44× | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.opcf.depth.2026-06-30.operating_cash_flow_m | Operating cash flow — period end 2026-06-30 | $510.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-31.operating_cash_flow_m | Operating cash flow — period end 2026-03-31 | $409.88M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-06-30.capex_m | Capital expenditure (reported) — period end 2026-06-30 | −$96.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-31.capex_m | Capital expenditure (reported) — period end 2026-03-31 | −$136.30M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.operating_cash_flow_m | Operating cash flow — period end 2025-12-31 | $658.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.capex_m | Capital expenditure (reported) — period end 2025-12-31 | −$201.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-30.operating_cash_flow_m | Operating cash flow — period end 2025-09-30 | $698.77M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-30.capex_m | Capital expenditure (reported) — period end 2025-09-30 | −$160.08M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
earn.pt_range | Analyst price target, low to high | $35.00 – $85.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied | |
earn.pt_consensus | Consensus analyst price target | $74.88 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied | |
earn.pt_median | Median analyst price target | $80.50 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied | |
own.institutions.depth.ownership_pct | Institutional ownership | 49.4% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.ownership_pct_previous_quarter | Previous quarter · ownership | 46.8% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.institutions.depth.holders | Reporting holders | 670 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.holders_previous_quarter | Previous quarter · holders | 689 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.top_holders.depth.holder_0.shares | Vanguard Capital Management LLC — shares in provider snapshot | 14,749,582 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_1.shares | Bank Of New York Mellon Corp — shares in provider snapshot | 13,057,962 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_2.shares | Norges Bank — shares in provider snapshot | 10,976,697 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_3.shares | Invesco Ltd. — shares in provider snapshot | 10,380,332 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_4.shares | Ako Capital Llp — shares in provider snapshot | 9,683,004 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. |
UNRECORDED — 2 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history | Reported versus estimated, recent quarters | EPS beat 6 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-09-29 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z 2.54 · Piotroski F 8 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-04 |
COMPUTED — 5 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
fin.mcap_to_cash | Market value per dollar of cash and short-term investments | 21.35× | — | COMPUTED | Computed on this page from the figures above — The market capitalisation printed on this page divided by cash and short-term investments of $1.46B at Jun 30, 2026. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. Market cap record date: 2026-10-02. Balance-sheet reference date: 2026-06-30. The inputs do not establish a single common source date for this ratio. |
div.ttm_per_share | Dividends per share, last 12 months (split-adjusted) | $0.36 | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history — Sum of 1 split-adjusted declared dividend with an ex-date in the 365 days to 2026-10-05, per current share. Ex-dates are not payment dates; special dividends are included. Not a declared annual rate. | |
div.ttm_yield | Dividend yield, last 12 months | 0.56% | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history and quote — Split-adjusted dividends with ex-dates in the trailing 365-day window divided by the packet price, on the same current-share basis. Price date follows the quote, latest price bar or packet-build day when unstamped. Not a forecast or declared annual rate. | |
earn.history.depth.2026-08-10.revenue_actual.comparison | Latest report · revenue vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported revenue ($2.79B) with the recorded estimate ($2.72B) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
earn.history.depth.2026-08-10.eps_actual.comparison | Latest report · EPS vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS ($0.8400) with the recorded estimate ($0.7700) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
OURS — 2 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 78 of 100 · Strong · pillars 79 / 69 / 70 / 80 / 53 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 78 (stored snapshot Oct 3, 2026) → 78 (current publication computed Oct 4, 2026) (0) | OURS | Stock Expert AI current score publication and immutable score snapshots |
Fact-family notes
- Quarterly statement note. Source series as of 2026-06-30. USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow. Applies to Fact IDs:
fin.q_table.depth.2026-06-30.revenue_k,fin.q_table.depth.2026-06-30.rd_k,fin.q_table.depth.2026-06-30.sga_k,fin.q_table.depth.2026-06-30.operating_result_k,fin.q_table.depth.2026-03-31.revenue_k,fin.q_table.depth.2026-03-31.rd_k,fin.q_table.depth.2026-03-31.sga_k,fin.q_table.depth.2026-03-31.operating_result_k,fin.q_table.depth.2025-12-31.revenue_k,fin.q_table.depth.2025-12-31.rd_k,fin.q_table.depth.2025-12-31.sga_k,fin.q_table.depth.2025-12-31.operating_result_k,fin.q_table.depth.2025-09-30.revenue_k,fin.q_table.depth.2025-09-30.rd_k,fin.q_table.depth.2025-09-30.sga_k,fin.q_table.depth.2025-09-30.operating_result_k. - Earnings-history note. Source series as of 2026-08-10. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-08-10.revenue_actual,earn.history.depth.2026-08-10.revenue_estimated,earn.history.depth.2026-08-10.revenue_actual.comparison,earn.history.depth.2026-08-10.eps_actual.comparison,earn.history.depth.2026-08-10.eps_actual,earn.history.depth.2026-08-10.eps_estimated,earn.history.depth.2026-05-05.revenue_actual,earn.history.depth.2026-05-05.revenue_estimated,earn.history.depth.2026-05-05.eps_actual,earn.history.depth.2026-05-05.eps_estimated,earn.history.depth.2026-02-24.revenue_actual,earn.history.depth.2026-02-24.revenue_estimated,earn.history.depth.2026-02-24.eps_actual,earn.history.depth.2026-02-24.eps_estimated,earn.history.depth.2025-11-11.revenue_actual,earn.history.depth.2025-11-11.revenue_estimated,earn.history.depth.2025-11-11.eps_actual,earn.history.depth.2025-11-11.eps_estimated. - Cash-flow note. Source series as of 2026-06-30. USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway. Applies to Fact IDs:
fin.opcf.depth.2026-06-30.operating_cash_flow_m,fin.opcf.depth.2026-03-31.operating_cash_flow_m,fin.opcf.depth.2026-06-30.capex_m,fin.opcf.depth.2026-03-31.capex_m,fin.opcf.depth.2025-12-31.operating_cash_flow_m,fin.opcf.depth.2025-12-31.capex_m,fin.opcf.depth.2025-09-30.operating_cash_flow_m,fin.opcf.depth.2025-09-30.capex_m.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-12
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Legal name | ALCON INC Our market-data provider lists the name as "Alcon Inc."; the filer's own record is used here. | 2026-09-12 | OFFICIAL | SEC EDGAR filer record |
| Ticker / exchange | ALC on NYSE | 2026-09-12 | OFFICIAL | SEC EDGAR filer record |
| Business description | Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. The company operates through two segments, Surgical and Vision Care. It offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. The company’s cataract products include Unity CS, LenSx laser system, Verion reference unit and Verion digital marker, ARGOS biometer, SMARTCATARACT health platform, NGENUITY 3D visualization system, LuxOR surgical ophthalmic microscope, and ORA system for intra-operative measurements; ADI cloud-based platform; and implantable products, including monofocal, Toric, and Presbyopia-Correcting IOLs, as well as delivery systems, such as AutonoMe and UltraSert. In addition, it provides Custom Pak surgical procedure packs vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, Grieshaber, MIVS instruments; scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit probes; and refractive surgery products, including WaveLight and Contoura Vision used for LASIK refractive procedure. Further, the company offers daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) company profile |
| Quarterly income statement (USD thousands) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements |
| Management outlook — dated call excerpts | Captured record · 4 entries
Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. | 2026-08-11 | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) |
| Annual revenue and net result (USD millions) | Captured record · 5 entries
| 2025-12-31 | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements |
| Reported versus estimated, last 8 quarters | Captured record · 8 entries
| 2026-08-10 | FMP | Financial Modeling Prep (FMP) earnings |
| Operating cash flow by quarter (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements |
| Cash, investments and debt | Total debt: $5.30B; Liquidity basis: cash and short-term investments; Total liabilities: $9.50B; Cash and short-term investments: $1.46B; Cash and investments: $2.23B; Long-term investments: $768.00M; Long-term investments classification: unclassified Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet |
| Cash and investment components | Total basis: cash short and long-term investments; Total: $2.23B; Cash and short-term investments: $1.46B; Long-term investments: $768.00M; Long-term investments classification: unclassified Sums the balance sheet's cash and short-term investments with its long-term investments.; The long-term investment field does not establish marketability; the sum is not a measure of available liquidity.; These provider fields do not establish investment access restrictions or explain differences from third-party cash figures. | 2026-06-30 | COMPUTED | Computed from the balance sheet |
| Cash and short-term investments over time (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's quarterly balance sheets |
| Cash decline over the reported window | To: 2026-06-30; From: 2024-09-30; Periods: 7; Cash basis: cash and short-term investments; Closing balance: $1.46B; Decline: $529.00M; Opening balance: $1.99B; Average change per period: $75.60M Change in cash, cash equivalents and short-term investments between the 2024-09-30 and 2026-06-30 balance sheets.; This is a balance change, not operating burn: financing and investing move it too.; Averaged over 7 reporting periods of unequal length. | 2026-06-30 | COMPUTED | Computed from reported balances |
| Trailing twelve-month ratio set | Quick ratio: 1.3; Current ratio: 2.09; Debt to equity: 0.25; Net margin: 5.9%; Gross margin: 56.5%; Operating margin: 9.9%; Return on assets: 2.1%; Return on equity: 2.9% Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. A ratio our provider could not compute is absent rather than shown as zero. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm |
| Distress and quality screens | Altman Z-score: 2.61; Piotroski F-score: 8 Altman Z below 1.8 is the conventional distress zone. The screen is built for manufacturers and industrials; for banks, insurers and property companies it is not a meaningful reading. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) financial scores |
| Recent dividends paid | Captured record · 4 entries
Declared amounts per share on their ex-dates. A single payment does not establish an annual rate, and a special dividend is not separated here. | 2026-05-06 | FMP | Financial Modeling Prep (FMP) dividend history |
| Next earnings report | Date: 2026-11-10; EPS estimate: $0.89 per share; Revenue estimate: $2.73B The date is our provider's estimate until the company confirms it. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) earnings calendar |
| Analyst revenue and earnings estimates (average) | Captured record · 4 entries
| 2026-09-12 | FMP | Financial Modeling Prep (FMP) analyst estimates |
Data provided for informational purposes only.